BofA analyst Jason Gerberry raised the firm’s price target on Alkermes (ALKS) to $34 from $33 and keeps a Neutral rating on the shares following what the firm calls “a good beat/raise 3Q.” While Q3 results were “solid,” the firm continues to see the upcoming Vibrance-2 readout in narcolepsy type-2 in November as “a stock driver,” says the analyst, who raised the firm’s FY25 and onward topline estimates by 1%-2% given strength in the base business.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Alkermes’ Strong Financial Performance and Strategic Moves Justify Buy Rating
- Warner Bros. Discovery upgraded, F5 downgraded: Wall Street’s top analyst calls
- Alkermes: Strong Financial Performance and Positive Outlook Justify Buy Rating
- Alkermes raises 2025 revenue view to $1.43B-$1.49B from $1.34B-$1.43B
- Alkermes reports Q3 EPS 49c, consensus 39c